industry-news Note: The following in an edited press release from Kedrion Biopharma. The original release can be read in its entirety here.

Kedrion Biopharma has gained approval from the U.S. Food and Drug Administration to package聽Ko膩te庐 Double Viral Inactivation (DVI) Antihemophilic Factor (human)聽with Mix2Vial™, a needle-free transfer device. The new packaging is designed to offer hemophilia patients optimized safety and convenience when reconstituting Ko膩te-DVI. Ko膩te-DVI is used in the treatment of hemophilia A, a rare, inherited condition characterized by a person鈥檚 inability to form effective blood clots following an injury, and by spontaneous bleeding into one鈥檚 joints. 鈥淪afety and convenience are two of the most important considerations hemophilia patients and their healthcare providers have when reconstituting lyophilized factor therapy,鈥 said Neal Fitzpatrick, Vice President, Commercial Head, North America at Kedrion Biopharma. 鈥淜nowing this, we are extremely pleased to be introducing Mix2Vial to Ko膩te-DVI users. Its needle-free design lowers the risk of accidental needle sticks, which may ensure an additional measure of safety and control when Ko膩te-DVI is being reconstituted.

In addition, the Mix2Vial reduces the number of steps involved in preparing product for use. We anticipate that patients, their parents, and healthcare treaters will welcome these advances.鈥 Before the availability of Mix2Vial, the reconstitution of Ko膩te-DVI required the use of a double-ended transfer needle and three steps (instead of two) to prepare product for use. The Mix2Vial is constructed of plastic with a built-in filter that works to enable fast, easy infusions.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.